4.1. Therapeutic indications

Epysqli is indicated in adults and children for the treatment of:

- Paroxysmal nocturnal haemoglobinuria (PNH).

Evidence of clinical benefit is demonstrated in patients with haemolysis with clinical symptom(s) indicative of high disease activity, regardless of transfusion history (see section 5.1).

- Atypical haemolytic uremic syndrome (aHUS) (see section 5.1).

4.2. Posology and method of administration

Epysqli must be administered by a healthcare professional and under the supervision of a physician experienced in the management of patients with haematological or renal disorders.

Home infusion may be considered for patients who have tolerated infusions well in the clinic. The decision of a patient to receive home infusions should be made after evaluation and recommendation from the treating physician. Home infusions should be performed by a qualified healthcare professional.

Posology

Paroxysmal Nocturnal Haemoglobinuria (PNH) in adults

The PNH dosing regimen for adult patients (≥ 18 years of age) consists of a 4-week initial phase followed by a maintenance phase:

• Initial phase: 600 mg of Epysqli administered via a 25 – 45 minute (35 minutes ± 10 minutes) intravenous infusion every week for the first 4 weeks.

• Maintenance phase: 900 mg of Epysqli administered via a 25 – 45 minute (35 minutes ± 10 minutes) intravenous infusion for the fifth week, followed by 900 mg of Epysqli administered via a 25 – 45 minute (35 minutes ± 10 minutes) intravenous infusion every 14 ± 2 days (see section 5.1).

atypical Haemolytic Uremic Syndrome (aHUS) in adults

The aHUS dosing regimen for adult patients (≥ 18 years of age) consists of a 4 week initial phase followed by a maintenance phase:

• Initial phase: 900 mg of Epysqli administered via a 25 – 45 minute (35 minutes ± 10 minutes) intravenous infusion every week for the first 4 weeks.

• Maintenance phase: 1,200 mg of Epysqli administered via a 25 – 45 minute (35 minutes ± 10 minutes) intravenous infusion for the fifth week, followed by 1,200 mg of Epysqli administered via a 25 – 45 minute (35 minutes ± 10 minutes) intravenous infusion every 14 ± 2 days (see section 5.1).

Paediatric patients in PNH or aHUSPaediatric PNH or aHUS patients with body weight ≥ 40 kg are treated with the adult dosing recommendations.

In paediatric PNH and aHUS patients with body weight below 40 kg, Epysqli dosing regimen consists of:

Table 1: Epysqli dose for paediatric patients

Patient body weight

Initial phase

Maintenance phase

30 to < 40 kg

600 mg weekly for the first 2 weeks

900 mg at week 3; then 900 mg every 2 weeks

20 to < 30 kg

600 mg weekly for the first 2 weeks

600 mg at week 3; then 600 mg every 2 weeks

10 to < 20 kg

600 mg single dose at week 1

300 mg at week 2; then 300 mg every 2 weeks

5 to < 10 kg

300 mg single dose at week 1

300 mg at week 2; then 300 mg every 3 weeks

Epysqli has not been studied in patients with PNH who weigh less than 40kg. The posology of Epysqli to be used in paediatric patients with PNH patients weighing less than 40 kg is identical to the weight-based dose recommendation provided for paediatric patients with aHUS. Based on the pharmacokinetic (PK)/pharmacodynamic (PD) data available in patients with aHUS and PNH treated with eculizumab, this body-weight based dose regimen for paediatric patients is expected to result in an efficacy and safety profile similar to that in adults.

Supplemental dosing of Epysqli is required in the setting of concomitant plasmapheresis (PP), plasma exchange (PE), or fresh frozen plasma infusion (PI) as described below:

Type of plasma intervention

Most recent Epysqli dose

Supplemental Epysqli dose with each PP/PE/PI Intervention

Timing of supplemental Epysqli dose

Plasmapheresis or plasma exchange

300 mg

300 mg per each plasmapheresis or plasma exchange session

Within 60 minutes after each plasmapheresis or plasma exchange

≥ 600 mg

600 mg per each plasmapheresis or plasma exchange session

Fresh frozen plasma infusion

≥ 300 mg

300 mg per infusion of fresh frozen plasma

60 minutes prior to each infusion of fresh frozen plasma

Abbreviations: PP/PE/PI = plasmapheresis/plasma exchange/plasma infusion

Supplemental dose of Epysqli is required in the setting of concomitant intravenous immunoglobulin (IVIg) treatment as described below (see also Section 4.5):

Most recent Epysqli dose

Supplemental Epysqli dose

Timing of supplemental Epysqli dose

≥ 900 mg

600 mg per IVIg cycle

As soon as possible after IVIg cycle

≤ 600 mg

300 mg per IVIg cycle

Abbreviation: IVIg = intravenous immunoglobulin

Treatment monitoring

aHUS patients should be monitored for signs and symptoms of thrombotic microangiopathy (TMA) (see section 4.4 aHUS laboratory monitoring).

Epysqli treatment is recommended to continue for the patient's lifetime, unless the discontinuation of Epysqli is clinically indicated (see section 4.4).

Special populations

Elderly Epysqli may be administered to patients aged 65 years and over. There is no evidence to suggest that any special precautions are needed when older people are treated – although experience with eculizumab in this patient population is still limited.

Renal impairment No dose adjustment is required for patients with renal impairment (see section 5.1).

Hepatic impairment The safety and efficacy of eculizumab have not been studied in patients with hepatic impairment.

Method of administration

Epysqli should not be administered as an intravenous push or bolus injection. Epysqli should only be administered via intravenous infusion as described below.

For instructions on dilution of the medicinal product before administration, see section 6.6.The diluted solution of Epysqli should be administered by intravenous infusion over 25 – 45 minutes (35 minutes ± 10 minutes) in adults and 1-4 hours in paediatric patients under 18 years of age via gravity feed, a syringe-type pump, or an infusion pump.

Patients should be monitored for one hour following infusion. If an adverse event occurs during the administration of Epysqli, the infusion may be slowed or stopped at the discretion of the physician. If the infusion is slowed, the total infusion time may not exceed two hours in adults and four hours in paediatric patients under 18 years of age.

There is limited safety data supporting home-based infusions, additional precautions in the home setting such as availability of emergency treatment of infusion reactions or anaphylaxis are recommended. Infusion reactions are described in sections 4.4 and 4.8 on the SmPC.

4.3. Contraindications

Hypersensitivity to the active substance, CHO cell products or to any of the excipients listed in section 6.1.

Eculizumab therapy must not be initiated in patients (see section 4.4):

- with unresolved Neisseria meningitidis infection

- who are not currently vaccinated against Neisseria meningitidis unless they receive prophylactic treatment with appropriate antibiotics until 2 weeks after vaccination.

4.4. Special warnings and precautions for use

TraceabilityIn order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded. Eculizumab is not expected to affect the aplastic component of anaemia in patients with PNH.

Meningococcal InfectionDue to its mechanism of action, the use of eculizumab increases the patient's susceptibility to meningococcal infection (Neisseria meningitidis). Meningococcal disease due to any serogroup may occur. To reduce the risk of infection, all patients must be vaccinated at least 2 weeks prior to receiving eculizumab unless the risk of delaying eculizumab therapy outweighs the risks of developing a meningococcal infection. Patients who initiate eculizumab treatment less than 2 weeks after receiving a tetravalent meningococcal vaccine must receive treatment with appropriate prophylactic antibiotics until 2 weeks after vaccination. Vaccines against all available serogroups including A, C, Y, W 135, and B are recommended in preventing the commonly pathogenic meningococcal serogroups. Patients must be vaccinated and revaccinated according to current national guidelines for vaccination use.

Vaccination may further activate complement. As a result, patients with complement-mediated diseases, including PNH and aHUS, may experience increased signs and symptoms of their underlying disease, such as haemolysis (PNH) or TMA (aHUS). Therefore, patients should be closely monitored for disease symptoms after recommended vaccination.

Vaccination may not be sufficient to prevent meningococcal infection. Consideration should be given to official guidance on the appropriate use of antibacterial agents. Cases of serious or fatal meningococcal infections have been reported in eculizumab-treated patients. Sepsis is a common presentation of meningococcal infections in patients treated with eculizumab (see section 4.8). All patients should be monitored for early signs of meningococcal infection, evaluated immediately if infection is suspected, and treated with appropriate antibiotics if necessary. Patients should be informed of these signs and symptoms and steps taken to seek medical care immediately. Physicians must discuss the benefits and risks of eculizumab therapy with patients and provide them with a patient guide and a patient card (see Package Leaflet for a description).

Other Systemic InfectionsDue to its mechanism of action, eculizumab therapy should be administered with caution to patients with active systemic infections. Patients may have increased susceptibility to infections, especially with Neisseria and encapsulated bacteria. Serious infections with Neisseria species (other than Neisseria meningitidis), including disseminated gonococcal infections, have been reported.Patients should be provided with information from the Package Leaflet to increase their awareness of potential serious infections and the signs and symptoms of them. Physicians should advise patients about gonorrhoea prevention.

Infusion ReactionsAdministration of eculizumab may result in infusion reactions or immunogenicity that could cause allergic or hypersensitivity reactions (including anaphylaxis). In clinical trials of the reference medicinal product, 1 (0.9%) refractory generalised myasthenia gravis (gMG) patient experienced an infusion reaction which required discontinuation of eculizumab. No PNH or aHUS paediatric patients experienced an infusion reaction which required discontinuation of eculizumab. Eculizumab administration should be interrupted in all patients experiencing severe infusion reactions and appropriate medical therapy administered.

ImmunogenicityAnti-eculizumab antibodies may develop during eculizumab treatment. No apparent correlation of antibody development with clinical response or adverse events has been observed.

ImmunisationPrior to initiating eculizumab therapy, it is recommended that patients initiate immunisations according to current immunisation guidelines. Additionally, all patients must be vaccinated against meningococcal infections at least 2 weeks prior to receiving eculizumab unless the risk of delaying eculizumab therapy outweighs the risks of developing a meningococcal infection. Patients who initiate eculizumab treatment less than 2 weeks after receiving a tetravalent meningococcal vaccine must receive treatment with appropriate prophylactic antibiotics until 2 weeks after vaccination. Vaccines against all available serogroups including A, C, Y, W 135 and B are recommended in preventing the commonly pathogenic meningococcal serogroups. Patients must be vaccinated and revaccinated according to current national guidelines for vaccination use (see Meningococcal Infection).

Patients less than 18 years of age must be vaccinated against Haemophilus influenzae and pneumococcal infections, and strictly need to adhere to the national vaccination recommendations for each age group.

Vaccination may further activate complement. As a result, patients with complement-mediated diseases, including PNH and aHUS may experience increased signs and symptoms of their underlying disease, such as haemolysis (PNH) or TMA (aHUS). Therefore, patients should be closely monitored for disease symptoms after recommended vaccination.

Anticoagulant therapyTreatment with eculizumab should not alter anticoagulant management.

PNH Laboratory MonitoringPNH patients should be monitored for signs and symptoms of intravascular haemolysis, including serum lactate dehydrogenase (LDH) levels. PNH patients receiving eculizumab therapy should be similarly monitored for intravascular haemolysis by measuring LDH levels, and may require dose adjustment within the recommended 14±2 day dosing schedule during the maintenance phase (up to every 12 days).

aHUS Laboratory MonitoringaHUS patients receiving eculizumab therapy should be monitored for thrombotic microangiopathy by measuring platelet counts, serum LDH and serum creatinine, and may require dose adjustment within the recommended 14±2 day dosing schedule during the maintenance phase (up to every 12 days).

Treatment Discontinuation for PNHIf patients discontinue treatment with eculizumab they should be closely monitored for signs and symptoms of serious intravascular haemolysis. Serious haemolysis is identified by serum LDH levels greater than the pre-treatment level, along with any of the following: greater than 25% absolute decrease in PNH clone size (in the absence of dilution due to transfusion) in one week or less; a haemoglobin level of < 5 g/dL or a decrease of > 4 g/dL in one week or less; angina; change in mental status; a 50% increase in serum creatinine level; or thrombosis. Monitor any patient who discontinues eculizumab for at least 8 weeks to detect serious haemolysis and other reactions.If serious haemolysis occurs after eculizumab discontinuation, consider the following procedures/treatments: blood transfusion (packed RBCs), or exchange transfusion if the PNH RBCs are > 50 % of the total RBCs by flow cytometry; anticoagulation; corticosteroids; or reinstitution of eculizumab. In PNH clinical trials, 16 patients discontinued the eculizumab treatment regimen. Serious haemolysis was not observed.

Treatment Discontinuation for aHUSThrombotic microangiopathy (TMA) complications have been observed as early as 4 weeks and up to 127 weeks following discontinuation of eculizumab treatment in some patients. Discontinuation of treatment should only be considered if medically justified.

In aHUS clinical studies, 61 patients (21 paediatric patients) discontinued eculizumab treatment with a median follow-up period of 24 weeks. Fifteen severe thrombotic microangiopathy (TMA) complications in 12 patients were observed following treatment discontinuation, and 2 severe TMA complications occurred in an additional 2 patients that received a reduced dosing regimen of eculizumab outside of the approved dosing regimen (see section 4.2). Severe TMA complications occurred in patients regardless of whether they had an identified genetic mutation, high risk polymorphism or auto-antibody. Additional serious medical complications occurred in these patients including severe worsening of kidney function, disease-related hospitalization and progression to end stage renal disease requiring dialysis. Despite eculizumab re-initiation following discontinuation, progression to end stage renal disease occurred in one patient. If aHUS patients discontinue treatment with eculizumab, they should be monitored closely for signs and symptoms of severe thrombotic microangiopathy complications. Monitoring may be insufficient to predict or prevent severe thrombotic microangiopathy complications in patients with aHUS after discontinuation of eculizumab. Severe thrombotic microangiopathy complications post discontinuation can be identified by (i) any two, or repeated measurement of any one, of the following: a decrease in platelet count of 25% or more as compared to either baseline or to peak platelet count during eculizumab treatment; an increase in serum creatinine of 25% or more as compared to baseline or to nadir during eculizumab treatment; or, an increase in serum LDH of 25% or more as compared to baseline or to nadir during eculizumab treatment; or (ii) any one of the following: a change in mental status or seizures; angina or dyspnoea; or thrombosis. If severe thrombotic microangiopathy complications occur after eculizumab discontinuation, consider reinstitution of eculizumab treatment, supportive care with PE/PI, or appropriate organ-specific supportive measures including renal support with dialysis, respiratory support with mechanical ventilation or anticoagulation.

Educational materialsAll physicians who intend to prescribe eculizumab must ensure they are familiar with the guide for Healthcare Professionals to prescribing. Physicians must discuss the benefits and risks of eculizumab therapy with patients and provide them with a Patient guide and a patient card.Patients should be instructed that if they develop fever, headache accompanied with fever and/or stiff neck or sensitivity to light, they should immediately seek medical care as these signs may be indicative of meningococcal infection.

Excipients with known effect

Sodium Once diluted with sodium chloride 9 mg/mL (0.9 %) solution for injection, this medicinal product contains 0.47 g sodium per 240 mL at the maximal dose, equivalent to 23.4 % of the WHO recommended maximum daily intake of 2 g sodium for an adult.Once diluted with sodium chloride 4.5 mg/mL (0.45 %) solution for injection, this medicinal product contains 0.26 g sodium per 240 mL at the maximal dose, equivalent to 12.8 % of the WHO recommended maximum daily intake of 2 g sodium for an adult.

Polysorbate 80

This medicinal product contains 6.6 mg of polysorbate 80 in each vial (30 mL vial) which is equivalent to 0.66 mg/kg or less at the maximum dose for adult patients and paediatric patients with body weight more than 10 kg and is equivalent to 1.32 mg/kg or less at the maximum dose for paediatric patients with body weight 5 to <10 kg. Polysorbates may cause allergic reactions.

4.5. Interaction with other medicinal products and other forms of interaction

No interaction studies have been performed. Based on the potential inhibitory effect of eculizumab on complement-dependent cytotoxicity of rituximab, eculizumab may reduce the expected pharmacodynamic effects of rituximab.

Plasma exchange (PE), plasmapheresis (PP), fresh frozen plasma infusion (PI) and intravenous immunoglobulin (IVIg) have been shown to reduce eculizumab serum levels. A supplemental dose of eculizumab is required in these settings. See Section 4.2 for guidance in case of concomitant PE, PP, PI, or IVIg treatment.

Concomitant use of eculizumab with intravenous immunoglobulin (IVIg) may reduce effectiveness of eculizumab. Closely monitor for reduced effectiveness of eculizumab.

Concomitant use of eculizumab with neonatal Fc receptor (FcRn) blockers may lower systemic exposures and reduce effectiveness of eculizumab. Closely monitor for reduced effectiveness of eculizumab.

4.6. Fertility, pregnancy and lactation

The use of adequate contraception to prevent pregnancy and for at least 5 months after the last dose of treatment with eculizumab should be considered for women of childbearing potential.

PregnancyThere are no well-controlled studies in pregnant women treated with eculizumab. Data on a limited number of pregnancies exposed to eculizumab (less than 300 pregnancy outcomes) indicate there is no increased risk of foetal malformation or foetal-neonatal toxicity. However, due to the lack of well-controlled studies, uncertainties remain. Therefore, an individual risk benefit analysis is recommended before starting and during treatment with eculizumab in pregnant women. Should such a treatment be considered necessary during pregnancy, a close maternal and foetal monitoring according to local guidelines is recommended.

Animal reproduction studies have not been conducted with eculizumab (see section 5.3).

Human IgG are known to cross the human placental barrier, and thus eculizumab may potentially cause terminal complement inhibition in the foetal circulation. Therefore, eculizumab should be given to a pregnant woman only if clearly needed.

Breast-feedingNo effects on the breastfed newborn / infant are anticipated as limited data available suggest that eculizumab is not excreted in human breast milk. However, due to the limitations of the available data, the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for eculizumab and any potential adverse events on the breastfed child from eculizumab or from the underlying maternal condition.

FertilityNo specific study of eculizumab on fertility has been conducted.

4.7. Effects on ability to drive and use machines

Eculizumab has no or negligible influence on the ability to drive and use machines.

4.8. Undesirable effects

Summary of the safety profileSupportive safety data were obtained from 33 completed clinical trials that included 1 555 patients exposed to eculizumab in complement-mediated disease populations, including PNH, aHUS, gMG and Neuromyelitis Optica Spectrum Disorder (NMOSD). The most common adverse reaction was headache, (occurred mostly in the initial phase of dosing), and the most serious adverse reaction was meningococcal infection.

Tabulated list of adverse reactionsTable 2 gives the adverse reactions observed from spontaneous reporting and in eculizumab completed clinical trials, including PNH, aHUS, refractory gMG and NMOSD studies. Adverse reactions reported at a very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1 000 to < 1/100) or rare (≥ 1/10 000 to < 1/1 000) frequency with eculizumab, are listed by system organ class and preferred term. Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.

Table 2: Adverse reactions reported in eculizumab clinical trials, including patients with PNH, aHUS, refractory gMG and NMOSD as well as from post marketing experience

MedDRA system organ class

Very common(≥1/10)

Common(≥1/100 to <1/10)

Uncommon(≥1/1 000 to <1/100)

Rare(≥1/10000 to <1/1000)

Infection and infestations

Pneumonia, Upper respiratory tract infection, Bronchitis, Nasopharyngitis, Urinary tract infection, Oral Herpes

Meningococcal infectionb, Sepsis, Septic shock, Peritonitis, Lower respiratory tract infection, Fungal infection, Viral infection, Abscessa, Cellulitis, Influenza, Gastrointestinal infection, Cystitis, Infection, Sinusitis, Gingivitis

Aspergillus infectionc, Arthritis bacterialc, Genitourinary tract gonococcal infection, Haemophilus infection, Impetigo

Neoplasms benign, malignant and unspecified (including cysts and polyps)

Malignant melanoma, Myelodysplastic syndrome

Blood and lymphatic system disorders

Leukopenia, Anaemia

Thrombocytopenia, Lymphopenia

Haemolysis*, Abnormal clotting factor, Red blood cell agglutination, Coagulopathy

Immune system disorders

Anaphylactic reaction, Hypersensitivity

Endocrine disorders

Grave's disease

Metabolism and nutrition disorders

Decreased appetite

Psychiatric disorders

Insomnia

Depression, Anxiety, Mood swings, Sleep disorder

Abnormal dreams

Nervous system disorders

Headache

Dizziness

Paraesthesia, Tremor, Dysgeusia, Syncope

Eye disorders

Vision blurred

Conjunctival irritation

Ear and labyrinth disorders

Tinnitus, Vertigo

Cardiac disorders

Palpitation

Vascular disorders

Hypertension

Accelerated hypertension, Hypotension, Hot flush, Vein disorder

Haematoma

Respiratory, thoracic and mediastinal disorders

Cough, Oropharyngeal pain

Dyspnoea, Epistaxis, Throat irritation, Nasal congestion, Rhinorrhoea

Gastrointestinal disorders

Diarrhoea, Vomiting, Nausea, Abdominal pain

Constipation, Dyspepsia, Abdominal distension

Gastroesophageal reflux disease, Gingival pain

Hepatobiliary disorders

Jaundice

Skin and subcutaneous tissue disorders

Rash, Pruritus, Alopecia

Urticaria, Erythema, Petechiae, Hyperhidrosis, Dry skin, Dermatitis

Skin depigmentation

Musculoskeletal and connective tissue disorders

Arthralgia, Myalgia, Pain in extremity

Muscle spasms, Bone pain, Back pain, Neck pain

Trismus, Joint swelling

Renal and urinary disorders

Renal impairment, Dysuria, Haematuria

Reproductive system and breast disorders

Spontaneous penile erection

Menstrual disorder

General disorders and administration site conditions

Pyrexia, Fatigue, Influenza-like illness

Edema, Chest discomfort, Asthenia, Chest pain, Infusion site pain, Chills

Extravasation, Infusion site paraesthesia, Feeling hot

Investigations

Alanine aminotransferase increased, Aspartate aminotransferase increased, Gamma- glutamyltransferase increased, Haematocrit decreased, Haemoglobin decreased

Coombs test positivec

Injury, poisoning and procedural complication

Infusion-related reaction

Included Studies: Asthma (C07-002), aHUS(C08-002, C08-003, C10-003, C10-004), Dermatomyositis (C99-006), refractory gMG (C08-001, ECU-MG-301, ECU-MG-302, ECU-MG-303), Neuromyelitis Optica Spectrum Disorder (ECU-NMO-301, ECU-NMO-302), IMG (C99-004, E99-004), PNH (C02-001, C04-001, C04-002, C06-002, C07-001, E02-001, E05-001, E07-001, M07-005, X03-001, X03-001A), Psoriasis (C99-007), RA (C01-004, C97-001, C99-001, E01-004, E99-001), STEC-HUS (C11-001), SLE (C97-002). MedDRA version 26.1.*See paragraph Description of selected adverse reactions.a Abscess includes the following group of PTs: Abscess limb, Colonic abscess, Renal abscess, Subcutaneous abscess, Tooth abscess, Liver abscess, Perirectal abscess, Rectal abscess.b Meningococcal infection includes the following group of PTs: Meningococcal infection, Meningococcal sepsis, Meningitis meningococcal.cADRs identified in post marketing reports

Description of selected adverse reactionsIn all clinical trials, the most serious adverse reaction was meningococcal sepsis which is a common presentation of meningococcal infections in patients treated with eculizumab (see section 4.4).Other cases of Neisseria species have been reported including sepsis with Neisseria gonorrhoeae, Neisseria sicca/subflava, Neisseria spp unspecified.

Antibodies to eculizumab were detected in patients. As with all proteins there is a potential for immunogenicity.

Cases of haemolysis have been reported in the setting of missed or delayed eculizumab dose in PNH clinical trials (see also section 4.4).

Cases of thrombotic microangiopathy complication have been reported in the setting of missed or delayed eculizumab dose in aHUS clinical trials.

Paediatric populationIn children and adolescent PNH patients (aged 11 years to less than 18 years) included in the paediatric PNH Study M07-005, the safety profile appeared similar to that observed in adult patients. The most common adverse reaction reported in paediatric patients was headache.

In paediatric aHUS patients (aged 2 months to less than 18 years) included in the aHUS studies C08-002, C08-003, C09-001r and C10-003, the safety profile appeared similar to that observed in adult aHUS patients. The safety profiles in the different paediatric subsets of age appear similar.

Other special populations

Elderly No overall differences in safety were reported between elderly (≥ 65 years) and younger refractory gMG patients (< 65 years) in eculizumab study.

Patients with other diseases Safety Data from Other Clinical trials Supportive safety data were obtained in 12 completed clinical trials that included 934 patients exposed to eculizumab in other disease populations other than PNH, aHUS, refractory gMG or NMOSD. There was an un-vaccinated patient diagnosed with idiopathic membranous glomerulonephropathy who experienced meningococcal meningitis. Adverse reactions reported in patients with disease other than PNH, aHUS, refractory gMG or NMOSD were similar to those reported in patients with PNH, aHUS, refractory gMG or NMOSD (see Table 2 above). No specific adverse reactions have emerged from these clinical trials.

Reporting of suspected adverse reactionsReporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9. Overdose

No case of overdose has been reported in any of the clinical studies.